Skip to Content
Merck
CN

G0600000

Griseofulvin

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(2S)-trans-7-Chloro-2′,4,6-trimethoxy-6′-methylspiro(benzofuran-2[3H],1′-[2]cyclohexene)-3,4′-dione

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H17ClO6
CAS Number:
126-07-8
Molecular Weight:
352.77
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329799817
MDL number:
MFCD00082343
Beilstein/REAXYS Number:
95226

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1

SMILES string

ClC1=C(O[C@@]2(C(OC)=CC(C[C@H]2C)=O)C3=O)C3=C(OC)C=C1OC

InChI key

DDUHZTYCFQRHIY-RBHXEPJQSA-N

grade

pharmaceutical primary standard

API family

griseofulvin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Griseofulvin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Carc. 2 - Repr. 1B - Skin Sens. 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Absorption, distribution, metabolism, and excretion of griseofulvin in man and animals.
C Lin et al.
Drug metabolism reviews, 4(1), 75-95 (1975-01-01)
O E Araujo et al.
DICP : the annals of pharmacotherapy, 24(9), 851-854 (1990-09-01)
Griseofulvin is the oral antifungal agent of choice for the treatment of dermatophytoses. This article reviews the history, pharmacokinetics, adverse reactions, and traditional therapeutic applications of griseofulvin. In addition, reports since 1960 of the use of the drug in the
B E Elewski
Journal of the American Academy of Dermatology, 40(6 Pt 2), S27-S30 (1999-06-15)
Tinea capitis is a common pediatric scalp infection caused by dermatophytes. Topical therapy alone is ineffective, so oral griseofulvin has traditionally been the standard treatment. The new antimycotic agents itraconazole, terbinafine, and fluconazole represent effective treatment alternatives that have fewer
S Knasmüller et al.
Critical reviews in toxicology, 27(5), 495-537 (1997-11-05)
Griseofulvin (GF) has been in use for more than 30 years as a pharmaceutical drug in humans for the treatment of dermatomycoses. Animal studies give clear evidence that it causes a variety of acute and chronic toxic effects, including liver
G Mion et al.
Annales francaises d'anesthesie et de reanimation, 9(3), 305-308 (1990-01-01)
A case of toxic epidermolysis (TE) with a fatal outcome is reported. It occurred after administration of 500 mg griseofulvin twice daily in a 19-year-old female patient. She developed the first skin lesions on the sixth day of treatment. All
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service